Mifepristone and misoprostol in California pharmacies after modifications to the Risk Evaluation and Mitigation Strategy Program.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 0234361 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0518 (Electronic) Linking ISSN: 00107824 NLM ISO Abbreviation: Contraception Subsets: MEDLINE
    • Publication Information:
      Publication: New York : Elsevier
      Original Publication: Los Altos, Calif., Geron-X.
    • Subject Terms:
      Misoprostol*/administration & dosage ; Mifepristone*/administration & dosage ; Pharmacies* ; Risk Evaluation and Mitigation*; Humans ; California ; Female ; Health Services Accessibility ; United States ; Abortion, Induced/methods ; Abortifacient Agents, Nonsteroidal/administration & dosage ; United States Food and Drug Administration ; Pregnancy
    • Abstract:
      In January 2023, the Food & Drug Administration modified the Risk Evaluation and Mitigation Strategy program regulating mifepristone to allow direct dispensation from retail pharmacies. In June 2023, we conducted a random, distributive survey of pharmacies in California using secret shopper methodology to investigate the feasibility of accessing mifepristone. One pharmacy had mifepristone immediately available (<24 hours), and misoprostol availability was limited. Accessibility to misoprostol varied by type of pharmacy (p < 0.01), but not by region. Even in a reproductive freedom state, access to mifepristone and misoprostol from outpatient retail pharmacies remains limited.
      (Copyright © 2024 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Medication abortion; Mifepristone; Misoprostol; Pharmacy; Risk Evaluation and Mitigation Strategy
    • Accession Number:
      0E43V0BB57 (Misoprostol)
      320T6RNW1F (Mifepristone)
      0 (Abortifacient Agents, Nonsteroidal)
    • Publication Date:
      Date Created: 20240528 Date Completed: 20240802 Latest Revision: 20240802
    • Publication Date:
      20240803
    • Accession Number:
      10.1016/j.contraception.2024.110506
    • Accession Number:
      38806139